Coherus Oncology, Inc. (CHRS)
$
1.36
Key metrics
Financial statements
Free cash flow per share
-0.7760
Market cap
157.6 Million
Price to sales ratio
1.8864
Debt to equity
0.0222
Current ratio
1.2381
Income quality
-0.5820
Average inventory
3.3 Million
ROE
-5.7472
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Coherus BioSciences, Inc. is a biopharmaceutical company that primarily targets the biosimilar and immuno-oncology markets in the United States. The company reported depreciation and amortization expenses of $5,276,000.00 reflecting the wear and tear of its assets. Its operating income ratio is -0.42 indicating the company's operational profitability margin. With a gross profit standing at $149,407,000.00 the company highlights its profitability from core operations. The weighted average number of shares outstanding is 114,553,537.00 shedding light on the company's shareholder base. Despite its efforts, the company reported a net loss of $28,507,000.00 indicating challenges in its operations. Coherus markets UDENYCA, a biosimilar to Neulasta, alongside a pipeline of products that include biosimilars for Humira, Avastin, and Lucentis. Additionally, the company is advancing the development of Toripalimab, a novel anti-PD-1 antibody for the second-line treatment of melanoma in China, as well as a Bevacizumab biosimilar and CHS-1420, an anti-TNF product candidate aiming to be an adalimumab biosimilar, along with a Ranibizumab biosimilar. Coherus holds license agreements with several prominent firms such as Selexis SA, AbbVie, Inc., Pfizer, Inc., Bioeq AG, Innovent Biologics (Suzhou) Co., Ltd., and Junshi Biosciences. Originally incorporated as BioGenerics, Inc., the company rebranded to Coherus BioSciences, Inc. in April 2012 and is headquartered in Redwood City, California. In the current market landscape, the stock is affordable at $1.61 which may attract budget-conscious investors. The stock has a high average trading volume of 1,149,982.00 indicating strong liquidity and interest from investors. With a market capitalization of $157,641,936.00 the company is classified as a small-cap player, positioning it uniquely within the industry. Coherus is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. The company continues to focus on its mission to provide accessible biopharmaceutical solutions while navigating the complexities of the healthcare market.
Is Coherus Oncology, Inc. (CHRS) a good investment?
Investing in Coherus Oncology, Inc. (CHRS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A+, with a Bullish outlook. Always conduct your own research before investing.
What is Coherus Oncology, Inc. (CHRS)'s stock forecast?
Analysts predict Coherus Oncology, Inc. stock to fluctuate between $0.71 (low) and $1.89 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Coherus Oncology, Inc.'s market capitalization?
As of 2025-12-19, Coherus Oncology, Inc.'s market cap is $157,641,936, based on 115,913,188 outstanding shares.
How does Coherus Oncology, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Coherus Oncology, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Coherus Oncology, Inc. (CHRS) stock?
To buy Coherus Oncology, Inc. (CHRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CHRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Coherus Oncology, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Coherus Oncology, Inc. perform in the last earnings report?
Revenue: $266,960,000 | EPS: $0.25 | Growth: -109.88%.
Where can I find Coherus Oncology, Inc.'s investor relations reports?
Visit https://www.coherus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Coherus Oncology, Inc.?
You can explore historical data from here
What is the all-time high and low for Coherus Oncology, Inc. stock?
All-time high: $19.32 (2021-11-16) | All-time low: $0.66 (2024-11-05).
What are the key trends affecting Coherus Oncology, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -
seekingalpha.com
Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Excellent. Great. Well, thank you, everyone, for joining us, joining our fireside chat with Coherus.
seekingalpha.com
Coherus Oncology, Inc. ( CHRS ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Rosh Dias Sameer Goregaoker Bryan McMichael - Chief Financial Officer Rosh Dias - Chief Medical Officer Conference Call Participants Michael Nedelcovych - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jason Mccarthy - Maxim Group LLC, Research Division Nick Quartapella - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.
zacks.com
Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.01 per share a year ago.
globenewswire.com
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer.
seekingalpha.com
Coherus Oncology, Inc. (NASDAQ:CHRS ) UBS Virtual Oncology Day October 1, 2025 1:00 PM EDT Company Participants Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Dennis Lanfear - Chairman, President & CEO Rosh Dias - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to the UBS Virtual Event. David Dai, you may begin.
seekingalpha.com
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited by a small patient population, so financial viability hinges on the success of novel pipeline agents like casdozokitug and CHS-114. Pipeline risks are significant, as neither IL-27 nor CCR8 targeting has shown efficacy in cancer yet, and early-stage biotech projects face high attrition rates.
seekingalpha.com
Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.
zacks.com
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.14 per share a year ago.
See all news
